Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 30:13:17588359211047352.
doi: 10.1177/17588359211047352. eCollection 2021.

Metastatic Urothelial Cancer: a rapidly changing treatment landscape

Carlos Stecca  1 , Osama Abdeljalil  1 , Srikala S Sridhar  2
Affiliations
Review

Metastatic Urothelial Cancer: a rapidly changing treatment landscape

Carlos Stecca et al. Ther Adv Med Oncol. .

Abstract

Despite significant progress, metastatic urothelial cancer remains an incurable condition with a limited life expectancy. Platinum-based chemotherapy is still the mainstay of treatment for metastatic disease, but immunotherapy, antibody drug conjugates, and targeted agents have shown encouraging results in several recent practice changing trials. In this review, we discuss the standard of care, recent therapeutic advances, ongoing clinical trials, and future perspectives in metastatic urothelial carcinoma.

Keywords: FGFR; antibody-drug conjugate; bladder cancer; immune checkpoint inhibitors; immunotherapy; metastatic urothelial carcinoma.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare that there is no conflict of interest.

Figures

Figure 1.
Figure 1.
Bladder cancer molecular classification.
Figure 2.
Figure 2.
Proposed algorithm for determining eligibility for neoadjuvant cisplatin-based chemotherapy in patients with MIBC. MIBC, muscle invasive bladder cancer.
Figure 3.
Figure 3.
Design of first line combination trials: chemotherapy and immune checkpoint inhibitors.
Figure 4.
Figure 4.
Trials with chemotherapy and immune checkpoint inhibitors combination. *Completed enrolment, awaiting results.
Figure 5.
Figure 5.
Mechanism of action of enfortumab-vedotin.
Figure 6.
Figure 6.
Management algorithm.
See this image and copyright information in PMC

References

    1. Sung H, Ferlay J, Siegel RL, et al.. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71: 209–249. - PubMed
    1. von der Maase H, Hansen SW, Roberts JT, et al.. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000; 18: 3068–3077. - PubMed
    1. American Cancer Society. Overview of bladder cancer, https://www.cancer.org/content/dam/CRC/PDF/Public/8557.00.pdf (accessed 23 March, 2020).
    1. Powles T, Park SH, Voog E, et al.. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020; 383: 1218–1230. - PubMed
    1. Seront E, Machiels JP.Molecular biology and targeted therapies for urothelial carcinoma. Cancer Treat Rev 2015; 41: 341–353. - PubMed

LinkOut - more resources